First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.

Item
http://www.wikidata.org/entity/Q34008520
Chinese Herbal Medicines as an Adjunctive Therapy for Unresectable Pancreatic Cancer: A Systematic Review and Meta-AnalysisTraditional Chinese medicine and cancer: History, present situation, and developmentDesigning a broad-spectrum integrative approach for cancer prevention and treatment.Aqueous extract of Polygonum bistorta modulates proteostasis by ROS-induced ER stress in human hepatoma cells.Safety surveillance of traditional Chinese medicine: current and futurePHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment.Sipjeondaebo-tang in patients with cancer with anorexia: a protocol for a pilot, randomised, controlled trialEvaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells.Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements.HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis.Second line treatment options for pancreatic cancer.Complementary Chinese Herbal Medicine Therapy Improves Survival of Patients With Pancreatic Cancer in Taiwan: A Nationwide Population-Based Cohort Study.Anticancer activities and mechanisms of heat-clearing and detoxicating traditional Chinese herbal medicine.The Traditional Chinese Medicine DangguiBuxue Tang Sensitizes Colorectal Cancer Cells to Chemoradiotherapy.Herbal Medicine Offered as an Initiative Therapeutic Option for the Management of Hepatocellular Carcinoma.Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway.
P2860

First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.

Item
http://www.wikidata.org/entity/Q34008520
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
First-in-human phase II trial ...... th advanced pancreatic cancer.
@ast
First-in-human phase II trial ...... th advanced pancreatic cancer.
@en
First-in-human phase II trial ...... th advanced pancreatic cancer.
@nl
type
label
First-in-human phase II trial ...... th advanced pancreatic cancer.
@ast
First-in-human phase II trial ...... th advanced pancreatic cancer.
@en
First-in-human phase II trial ...... th advanced pancreatic cancer.
@nl
prefLabel
First-in-human phase II trial ...... th advanced pancreatic cancer.
@ast
First-in-human phase II trial ...... th advanced pancreatic cancer.
@en
First-in-human phase II trial ...... th advanced pancreatic cancer.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921
P932
P356
P1433
P1476
First-in-human phase II trial ...... th advanced pancreatic cancer.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921
P932